Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study.
Fukuhara T, Saito H, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada PM, Yoshimori K, Nakachi I, Gemma PA, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara PK, Nukiwa PT, Morita PS, Kobayashi PK, Maemondo PM.
Fukuhara T, et al. Among authors: watanabe s, watanabe k.
EBioMedicine. 2020 Jul;57:102861. doi: 10.1016/j.ebiom.2020.102861. Epub 2020 Jul 3.
EBioMedicine. 2020.
PMID: 32629391
Free PMC article.
Clinical Trial.